​

Funding Round

Series A - Vivaldi Biosciences

Series A - Vivaldi Biosciences

Investment Firm

Overview

Vivaldi Biosciences develops influenza vaccines and therapeutics for seasonal and pandemic influenza.

Announced Date

Jan 21, 2009

Funding Type

Series A

Highlights

Location

New York, New York, United States, North America

Social

Investor Lead

NGN Capital

NGN Capital

NGN Capital is a early_stage_venture and late_stage_venture firm.

Bay City Capital

Bay City Capital

Bay City Capital is a debt and early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

2

Investor Name
Participant InvestorBay City Capital
Participant InvestorNGN Capital

Round Details and Background

Vivaldi Biosciences raised $23000000 on 2009-01-21 in Series A

Vivaldi Biosciences develops influenza vaccines and therapeutics for seasonal and pandemic influenza.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 21, 2009
Series A - Vivaldi Biosciences
2-23.0M
Jul 08, 2010
Venture Round - Vivaldi Biosciences
-2.0M
May 18, 2007
Series A - Vivaldi Biosciences
1-2.0M

Recent Activity

There is no recent news or activity for this profile.